Intrexon (NYSE: XON) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations and risk.

Earnings & Valuation

This table compares Intrexon and Codexis’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intrexon $190.93 million 8.57 -$186.61 million ($1.12) -12.10
Codexis $48.84 million 6.85 -$8.55 million ($0.65) -10.65

Codexis has lower revenue, but higher earnings than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Intrexon and Codexis, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intrexon 0 1 5 0 2.83
Codexis 0 1 3 0 2.75

Intrexon currently has a consensus target price of $38.50, indicating a potential upside of 184.13%. Codexis has a consensus target price of $7.81, indicating a potential upside of 12.90%. Given Intrexon’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Intrexon is more favorable than Codexis.


This table compares Intrexon and Codexis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intrexon -66.88% -18.68% -11.34%
Codexis -76.37% -140.02% -73.00%

Volatility and Risk

Intrexon has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Codexis has a beta of -1.6, suggesting that its share price is 260% less volatile than the S&P 500.

Insider and Institutional Ownership

77.4% of Intrexon shares are held by institutional investors. Comparatively, 65.7% of Codexis shares are held by institutional investors. 56.3% of Intrexon shares are held by company insiders. Comparatively, 9.8% of Codexis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


Intrexon beats Codexis on 11 of the 13 factors compared between the two stocks.

About Intrexon

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

About Codexis

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with's FREE daily email newsletter.